Skip to main content

Table 3 Odds ratio (OR) and 95% confidence interval (CI) of treatment regimen for pathologic complete response stratified by stromal tumor-infiltrating lymphocytes

From: Stromal tumor-infiltrating lymphocytes and pathologic response to neoadjuvant chemotherapy with the addition of platinum and pembrolizumab in TNBC: a single-center real-world study

Cohort

Regimen

Multivariable analysis

adjusted OR*

95% CI

P

All patients with sTILs

LPBC

Non-carboplatin

Ref.

  

Carboplatin

1.01

0.31–3.26

0.986

Pembrolizumab

6.40

1.09–37.47

0.040

Non-LPBC

Non-carboplatin

Ref.

  

Carboplatin

4.09

2.24–7.48

< 0.001

Pembrolizumab

4.47

2.30–8.67

< 0.001

Cohort

Regimen

Multivariable analysis

adjusted OR†

95% CI

P

cN + patients with sTILs

LPBC

Non-carboplatin

Ref.

  

Carboplatin

0.98

0.30–3.23

0.977

Pembrolizumab

11.45

1.17-112.43

0.036

Non-LPBC

Non-carboplatin

Ref.

  

Carboplatin

4.36

2.17–8.78

< 0.001

Pembrolizumab

3.94

1.91–8.13

< 0.001

  1. *Adjusted for age (≤ 50 vs. > 50), histologic grade (1 vs. 2 vs. 3), clinical tumor stage (1 vs. 2 vs. 3 vs. 4), and clinical nodal stage (0 vs. 1 vs. 2 vs. 3). †Adjusted for age (≤ 50 vs. > 50), histologic grade (1 vs. 2 vs. 3), clinical tumor stage (1 vs. 2 vs. 3 vs. 4), and clinical nodal stage (1 vs. 2 vs. 3). sTILs, stromal tumor-infiltrating lymphocytes; LPBC, lymphocyte-predominant breast cancer. Supplemental Table 1. Baseline characteristics of patients according to neoadjuvant chemotherapy regimen with baseline sTIL values (n = 369)
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us